Msaouel, P., Siefker-Radtke, A. O., Sweis, R., Mao, S., Rosenberg, J. E., Vaishampayan, U. N., … Iyer, G. V. (2020). 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). In Annals of Oncology (Vol. 31, pp. S556–S556). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.777

Msaouel, P., A. O. Siefker-Radtke, R. Sweis, S. Mao, J. E. Rosenberg, U. N. Vaishampayan, A Rezazadeh Kalebasty, et al. “705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).” In Annals of Oncology, 31:S556–S556. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.777.

Msaouel P, Siefker-Radtke AO, Sweis R, Mao S, Rosenberg JE, Vaishampayan UN, et al. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). In: Annals of Oncology. Elsevier BV; 2020. p. S556–S556.

Msaouel, P., et al. “705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S556–S556. Crossref, doi:10.1016/j.annonc.2020.08.777.

Msaouel P, Siefker-Radtke AO, Sweis R, Mao S, Rosenberg JE, Vaishampayan UN, Kalebasty AR, Pili R, Bupathi M, Nordquist LT, Shaffer DR, Davis N, Zhang T, Gandhi S, Christensen J, Shazer R, Yan X, Winter M, Der-Torossian H, Iyer GV. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Annals of Oncology. Elsevier BV; 2020. p. S556–S556.